Beranda › Kanker Esofagus › California › Baldwin Park
Uji klinis Kanker Esofagus di Baldwin Park, CA
14 studi untuk Kanker Esofagus mencari peserta di lokasi sekitar Baldwin Park (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- City of Hope National Medical Center, Duarte · 4 mi jauhnya
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- City of Hope - Duarte Cancer Center, Duarte · 4 mi jauhnya
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- City of Hope, Duarte · 4 mi jauhnya
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Menerima pesertaFase 1
- City of Hope National Medical Center, Duarte · 4 mi jauhnya
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- City of Hope, Duarte · 4 mi jauhnya
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- City of Hope Cancer Center, Duarte · 4 mi jauhnya
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Menerima pesertaFase 3
- City of Hope National Cancer Center, Duarte · 4 mi jauhnya
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- City of Hope, Duarte · 4 mi jauhnya
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Menerima pesertaFase 3
- Research Site, Duarte · 4 mi jauhnya
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Menerima pesertaFase 1
- City of Hope National Medical Center /ID# 276272, Duarte · 4 mi jauhnya
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Menerima peserta
- Beckman Research Institute of City of Hope, Duarte · 4 mi jauhnya
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- City of Hope, Duarte · 4 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Duarte · 4 mi jauhnya
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Menerima pesertaFase 1/2
- City of Hope, Duarte · 4 mi jauhnya
Uji klinis Kanker Esofagus di kota lain
- Houston, TX36 studi
- Boston, MA23 studi
- New York City, NY22 studi
- Nashville, TN19 studi
- St. Louis, MO17 studi
- Pittsburgh, PA15 studi
- Los Angeles, CA15 studi
- Grand Rapids, MI14 studi
- Philadelphia, PA13 studi
- San Antonio, TX12 studi
- Rochester, MN11 studi
- Chicago, IL11 studi
Studi lain di Baldwin Park
- Kanker Payudara44 studi
- Leukemia Mieloid Akut40 studi
- Kanker Kolorektal37 studi
- Kanker Paru Non-Sel Kecil36 studi
- Kanker (semua jenis)34 studi
- Kanker Prostat30 studi
- Kanker Metastatik30 studi
- Sindrom Mielodisplastik26 studi
- Kanker Ovarium25 studi
- Kanker Paru24 studi
- Mieloma Multipel23 studi
- Kanker Lambung22 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.